Raia Drogasil (BSP:RADL3) 3-Year EPS without NRI Growth Rate : 22.10% (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Raia Drogasil 3-Year EPS without NRI Growth Rate?

Raia Drogasil's EPS without NRI for the three months ended in Dec. 2023 was R$0.10.

During the past 12 months, Raia Drogasil's average EPS without NRI Growth Rate was -12.20% per year. During the past 3 years, the average EPS without NRI Growth Rate was 22.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 13.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was 19.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Raia Drogasil was 64.20% per year. The lowest was -14.70% per year. And the median was 24.05% per year.

Competitive Comparison of Raia Drogasil's 3-Year EPS without NRI Growth Rate

For the Pharmaceutical Retailers subindustry, Raia Drogasil's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Raia Drogasil's 3-Year EPS without NRI Growth Rate Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Raia Drogasil's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Raia Drogasil's 3-Year EPS without NRI Growth Rate falls into.

Raia Drogasil 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Raia Drogasil (BSP:RADL3) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Raia Drogasil 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Raia Drogasil's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Raia Drogasil (BSP:RADL3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Raia Drogasil SA (BSP:RADL3) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

RADLY:USA

Address

Avenue Corifeu de Azevedo Marques, 3097 Butanta, Sao Paulo, SP, BRA, 05339-9000

Website

https://ri.rd.com.br

Raia Drogasil SA is a large retail drug store operator in Brazil. The company's stores sell branded and generic medication, over-the-counter medicine, health and beauty aids, perfumery, cosmetics, household items, and personal care products. The company also acts as a pharmacy benefit manager, performing medical purchases with prenegotiated discounts. The majority of Raia Drogasil's revenue is generated through branded drug sales, while the bulk of the remaining revenue stems from perfumery, over-the-counter drugs, and generic drugs. The company owns a variety of stakes in operational subsidiaries.

Raia Drogasil (BSP:RADL3) Headlines

No Headlines